The scientific basis of our research & development is highly patient-centric. Our close collaboration with clinical centers and the APECED/APS-1 patient population enables us to understand the clinical status of individuals – manifestations or absence of disease and corresponding dynamic seroreactive profile. By focusing on the clinical outcome, we are able to apply serology, bioinformatics and advanced autoantibody cloning technologies in the hunt for novel autoantibodies that could have clinical benefit for wider populations of patients. Through clinically-led discovery, we are able to identify the autoantibodies which may mediate clinical benefit in a target-independent, unbiased manner.